Document is current
Any future updates will be listed below
-
Authors
van Spil, W. E. http://orcid.org/0000-0002-4980-5630
Bierma-Zeinstra, S. M. A.
Deveza, L. A.
Arden, N. K.
Bay-Jensen, A.-C.
Kraus, V. Byers
Carlesso, L.
Christensen, R.
Van Der Esch, M.
Kent, P.
Knoop, J.
Ladel, C.
Little, C. B.
Loeser, R. F.
Losina, E.
Mills, K.
Mobasheri, A.
Nelson, A. E.
Neogi, T.
Peat, G. M.
Rat, A.-C.
Steultjens, M.
Thomas, M. J.
Valdes, A. M.
Hunter, D. J.
-
Funding
Funding for this research was provided by:
National Institute for Health Research (ICA-CL-2016-02-014)
Oak Foundation (OCAY-13-309)
- License Information
-
More Information
Article History
Received: 21 October 2019
Accepted: 5 March 2020
First Online: 20 March 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: W.E. van Spil: none.S.M.A. Bierma-Zeinstra: provides consulting advice for Infirst Healthcare.N.K. Arden: provides consulting advice to Merck, Flexion, Freshfields Bruckhaus, Regeneron and Pfizer/Lilly.A.-C. Bay-Jensen: employee and shareholder at Nordic Bioscience. Partner and WP lead in the IMI-APPROACH consortium.V. Byers Kraus: none.L. Carlesso: none.R. Christensen: none.L.A. Deveza: received partial reimbursement of conference registration cost from Pfizer.M. Van Der Esch: none.P. Kent: none.J. Knoop: none.C. Ladel: employee of Merck KGaA.C.B. Little: conducts research funded by a number pharmaceutical companies through contracts negotiated with and finances controlled by the University of Sydney and/or Northern Sydney Local Health District; provides consulting advice to Galapagos Pharmaceuticas and Merck Serono.R.F. Loeser: provides consulting advice for Unity Biotechnology and is on the Scientific Advisory Board for Reginosine. He has received research funding from Bioventis.E. Losina: provided consulting advice for Regeneron. Receives research funding from Genentech.K. Mills: none.A. Mobasheri: provided consulting advice for Abbvie, Pfizer Consumer Health (PCH), Galapagos and Servier; received funding from the European Commission through the Structural and Social Funds programmes; received investigator initiated grant support from Merck KGaA.A.E. Nelson: provides consulting advice for Glaxo Smith Kline, receives royalties from Health Press, Ltd., provided presentations for MedScape and QuantiaMD.T. Neogi: none.G.M. Peat: none.A.-C. Rat: none.M. Steultjens: none.M.J. Thomas: none.A.M. Valdes: none.D.J. Hunter: provides consulting advice for Merck Serono, Tissuegene, and TLCBio.
